Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/465—Nicotine; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/34—Tobacco-abuse

Definitions

• the present invention relates to a method for gradually reducing or eliminating an individual's tobacco usage habit, in particular smoking, as well as the associated nicotine dependence that is created by tobacco use.
• the method described in this patent includes the steps of first recording over an approximately two week period, the times during which each cigarette is consumed. These time periods of smoking are referred to as consumption periods, which are not necessarily consecutive in time. Then, tobacco consumption gradually is decreased by replacing in an increasing number of consumption periods (up to 16 consumption periods) over a two week period, the use of tobacco with an alternative nicotine source such as Nicorette® nicotine-containing chewing gum (2 mg nicotine dosage), until no further tobacco is consumed. The nicotine in each piece of gum is a substitute for all the tobacco consumed during a consumption period. This level of consumption of the alternative nicotine source is maintained for approximately four weeks.
• the individual addresses the social and psychological reasons for smoking.
• the alternative nicotine source is eliminated at a rate of one consumption period per week for approximately 14-16 weeks, until no further alternative nicotine source is consumed.
• a second method described in U.S. Patent No. 5,055,478 includes an initial step of recording for approximately two weeks an individual's normal tobacco consumption pattern to identify the times of day during which tobacco is consumed, and the amount of tobacco consumed during these periods. Each day is then broken down into consumption periods of one hour each. Then, all tobacco consumption is abruptly stopped and an alternative nicotine source (approximately 1.5 to 1.75 mg. per consumption period) is administered for a period of about two weeks. As with the first method above, following cessation of smoking but while the individual is still receiving nicotine through the alternative nicotine source, the individual addresses the social and psychological reasons for smoking. The user then gradually decreases administration of the alternative nicotine source down to a lower level of approximately 1 mg per consumption period for approximately 10-18 days.
• Another method closely related to the methods described in U.S. Patent No. 5,055,478, combines smoking reduction with the use of nicotine replacement therapy.
• This method is described in Cooper et al., "New Hope for Heavy Smokers - The Cooper/Clayton Method to Stop Smoking".
• an alternative nicotine source is substituted for all consumption periods, and the individual immediately stops smoking.
• the remainder of the method is similar to the above method but elimination of the alternative nicotine source is to a maintenance level which is about one-third of the first maintenance level, followed by gradual reduction as in the final phase described above.
• the individual receives intensive person-to-person psychological intervention.
• Nicorette® Committed Quitters Calendar and Smoking- Cessation Service Yet another method of smoking cessation is described in a publication by SmithKline Beecham entitled "Nicorette® Committed Quitters Calendar and Smoking- Cessation Service.
• the user abruptly stops smoking and consumes one piece of Nicorette® gum (2 mg. or 4 mg. dosage, generic name nicotine polacrilex gum) every 1-2 hours consuming no more than 24 pieces per day for a six week period.
• week seven the individual cuts back to consuming one piece of Nicorette® gum every two hours and continues at this level for three weeks.
• week 10 the individual cuts back to one piece of Nicorette® gum every four hours.
• the individual During the twelve week period, the individual records the number of pieces of Nicorette® gum chewed and some activities the individual plans to do each day to help cope with not smoking.
• the calendar also provides helpful hints for dealing with cravings and the psychological aspects of quitting smoking, and a reminder of the amount of time invested in quitting.
• This invention is an improved method for reducing or eliminating tobacco usage, particularly smoking, and the nicotine dependency associated with tobacco usage by gradually decreasing an individual's tobacco usage over a time period while replacing nicotine from tobacco with an alternative nicotine source.
• the present invention as described herein, is a method to reduce or eliminate an individual's tobacco usage habit, in particular smoking, as well as the nicotine dependency associated with that habit.
• the method includes the step of gradually decreasing tobacco usage over a time period until the individual significantly reduces or eliminates tobacco usage.
• the reduction or elimination of tobacco usage is accomplished with or without behavioral intervention using nicotine replacement therapy such as an alternative nicotine source in conjunction with gradual tobacco use reduction.
• nicotine replacement therapy such as an alternative nicotine source in conjunction with gradual tobacco use reduction.
• Such a strategy expands the use of nicotine replacement therapy from an abrupt tabacco usage cessation to a gradual reduction.
• Gradually reducing the number of cigarettes smoked or other nicotine products used while replacing nicotine from tobacco with an alternative nicotine source aids in reducing nicotine cravings and withdrawal thereby facilitating reduction or elimination of tobacco usage.
• the alternative nicotine source can be any substance that contains nicotine and can be administered orally, systemically, through the mucous membranes, or otherwise that will deliver a dosage of nicotine approximating that delivered through smoking cigarettes or using another .
• Examples include suppository, snuff, inhaler, nasal spray, lozenge, sucker or the like.
• a preferred alternative nicotine source is a nicotine-containing chewing gum such as a nicotine polacrilex gum, preferably in about 2 mg. to about 4 mg. dosage based on the content of nicotine source.
• nicotine gum (2 mg. or 4 mg. dosage) is administered to a smoker who is instructed as follows:
• the Cochran-Mantel-Haenszel test controlling for site, was used to compare the difference in smoking cessation rates between the two treatment groups for smokers who selected 2 mg. or 4 mg. nicotine gum, separately.
• the Cochran-Mantel-Haenszel test (general association version), controlling for nicotine gum dose level and site, was performed to compare the difference in smoking cessation rates between the two treatment groups for all smokers.
• Placebo 817 Placebo: 830
• the present invention is also directed to a method of reducing tobacco usage without necessarily eliminating it. In this embodiment, once an individual reaches the level of tobacco usage desired, the individual continues to use the desired amount of tobacco while continuing to use nicotine-containing gum at that particular level.
• this alternative embodiment does not preclude having reduction of tobacco usage as the ultimate goal and then immediately continuing the method described in the first embodiment to cessation of tobacco usage, or maintaining the reduction regimen for a period and then continuing the method, according to the first embodiment, to cessation of tobacco usage.
• the methods described above are especially suited for modern smoking habits brought on by low tolerance for smoking as is found, for example, in a smoke-free workplace.
• the changing social views of smoking has forced smokers to consume tobacco less frequently and often in inhospitable environments.
• the steadily increasing use of an alternative nicotine source used in the above methods dulls the cravings that naturally arise during smokeless periods.
• Reduced cravings allow the user to stay within the plan more easily than if tobacco is eliminated entirely or if an alternative nicotine source is used only during time-spaced consumption periods.
• the methods of this invention are also intended to be applicable to reduction and/or cessation of the use of tobacco products other than cigarettes, such as use of smokeless tobacco such as chewing tobacco and snuff.
• the individual should understand and be made aware that nicotine-containing gum is a pharmaceutical product and must be used in a certain way to gain the benefit of it and of the present invention.
• the nicotine-containing gum should be chewed slowly until the individual notices a tingling sensation. Then, the individual should park the gum next to his or her cheek until the tingle is almost gone. After the tingle is gone, the individual should begin chewing again until the tingle returns, and then park the gum again. The individual should repeat this process until most of the tingle is gone, then discard the gum.
• alternative nicotine sources may include substances equivalent to or approximating nicotine including any and all known compounds and/or compositions, such as lobeline sulfate, that produce a similar physiological effect and may be substituted for the alternative nicotine source in accordance with the present invention.

Landscapes

• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Neurology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Addiction (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Manufacture Of Tobacco Products (AREA)
• Medicinal Preparation (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24006789

Family Applications (1)

Country Status (20)

Families Citing this family (14)

Citations (2)

Family Cites Families (1)

• 2000
  • 2000-02-15 US US09/504,560 patent/US6660754B1/en not_active Expired - Lifetime
• 2001
  • 2001-02-13 AR ARP010100637A patent/AR032440A1/es unknown
  • 2001-02-13 MY MYPI20010641A patent/MY127259A/en unknown
  • 2001-02-13 PE PE2001000154A patent/PE20011221A1/es not_active Application Discontinuation
  • 2001-02-14 EG EG20010130A patent/EG22199A/xx active
  • 2001-02-14 CO CO01011530A patent/CO5261581A1/es not_active Application Discontinuation
  • 2001-02-15 EP EP01910708A patent/EP1265610A4/en not_active Withdrawn
  • 2001-02-15 KR KR1020027010559A patent/KR20020075795A/ko not_active Withdrawn
  • 2001-02-15 CA CA002400353A patent/CA2400353A1/en not_active Abandoned
  • 2001-02-15 HU HU0301131A patent/HUP0301131A3/hu unknown
  • 2001-02-15 BR BR0108318-0A patent/BR0108318A/pt not_active Application Discontinuation
  • 2001-02-15 CN CN01804937A patent/CN1400901A/zh active Pending
  • 2001-02-15 EA EA200200765A patent/EA004184B1/ru not_active IP Right Cessation
  • 2001-02-15 CZ CZ20022766A patent/CZ20022766A3/cs unknown
  • 2001-02-15 AU AU38289/01A patent/AU782403B2/en not_active Expired
  • 2001-02-15 PL PL01357013A patent/PL357013A1/xx not_active Application Discontinuation
  • 2001-02-15 WO PCT/US2001/004798 patent/WO2001060364A1/en not_active Ceased
  • 2001-02-15 JP JP2001559461A patent/JP2003522789A/ja not_active Withdrawn
  • 2001-02-15 NZ NZ520586A patent/NZ520586A/en not_active IP Right Cessation
• 2002
  • 2002-09-09 ZA ZA200207217A patent/ZA200207217B/en unknown
• 2003
  • 2003-09-24 US US10/670,922 patent/US20040058966A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events